Experimental therapy shows promise in overcoming parp inhibitor resistance in ovarian cancer, suggesting new treatment avenues.
Key Points
PTT significantly prolonged survival in treated mice compared to untreated controls, indicating potential effectiveness against drug-resistant ovarian cancer.
Cytotoxicity testing revealed PTT's EC50 values range from 0.0021 to 0.80 MBq/mL in various ovarian cancer cell lines, supporting its efficacy.
PTT demonstrated 30-fold greater cytotoxicity than untargeted 211At, emphasizing its potential as a targeted therapy for ovarian cancer.
The study confirms that PTT's cytotoxicity relies on parp1 binding affinity rather than parp inhibitor sensitivity, indicating broader applicability.